Cersci Therapeutics Inc., of Dallas, said it received notice from the National Institute of Neurological Disorders and Stroke (NINDS) of the National Institutes of Health (NIH) that it has been awarded a phase I small business technology transfer (STTR) grant totaling over $220,000. The funds will support the preclinical development of small molecules for the treatment of migraine.